{"disease":{"id":"solid-tumor-cancer","name":"solid tumor cancer"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pf-07820435","indication_name":"Advanced solid tumors (non-small-cell lung cancer, melanoma)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07820435","generic_name":"pf-07820435","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications","drug_class":"Protease inhibitor","quality_score":null,"revenue":null,"mechanism":"PF-07820435 inhibits viral or cellular proteases to disrupt essential enzymatic processes required for viral replication or tumor cell survival."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06895681","title":"UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05534178","title":"Machine Learning Model to Predict HOLS and Mortality After Discharge in Hospitalized Oncologic Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Vall d'Hebron Institute of Oncology","has_results":false},{"nct_id":"NCT07035470","title":"Biological Age Predicts 90-Day Mortality in Advanced Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1615,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT07426094","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","has_results":false},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT05600933","title":"Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1200,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05216432","title":"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":930,"lead_sponsor_name":"Relay Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07303387","title":"Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":900,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT01231347","title":"QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT06028724","title":"A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","phase":"","overall_status":"RECRUITING","enrollment_count":782,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT06621563","title":"Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":780,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT06963502","title":"A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":762,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT02091141","title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":673,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05919264","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":595,"lead_sponsor_name":"Parabilis Medicines, Inc.","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07030569","title":"RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT04482309","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":477,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05581004","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT02178722","title":"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT05867251","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Avenzo Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07169994","title":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":414,"lead_sponsor_name":"MediLink Therapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT06775236","title":"Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":410,"lead_sponsor_name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","has_results":false},{"nct_id":"NCT04539496","title":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":402,"lead_sponsor_name":"Sihuan Pharmaceutical Holdings Group Ltd.","has_results":false},{"nct_id":"NCT06885424","title":"A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT04913285","title":"A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Pierre Fabre Medicament","has_results":false},{"nct_id":"NCT04930432","title":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Betta Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06545331","title":"Study of XB010 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT04844489","title":"Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People","phase":"NA","overall_status":"COMPLETED","enrollment_count":377,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05669430","title":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT07094204","title":"A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":364,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT02009449","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT07070518","title":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT06799637","title":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT04699188","title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":344,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07477743","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":331,"lead_sponsor_name":"HC Biopharma Inc.","has_results":false},{"nct_id":"NCT07381829","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":328,"lead_sponsor_name":"HC Biopharma Inc.","has_results":false},{"nct_id":"NCT04977453","title":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":317,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT04787042","title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":316,"lead_sponsor_name":"Simcha IL-18, Inc.","has_results":false},{"nct_id":"NCT05708950","title":"A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":314,"lead_sponsor_name":"Kineta Inc.","has_results":false},{"nct_id":"NCT02526017","title":"Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Five Prime Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT05604716","title":"Cross-sectional Follow-up on Digestive and Social Functions of SPN","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03866525","title":"OH2 Oncolytic Viral Therapy in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Binhui Biopharmaceutical Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}